

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/261624 A1

(43) International Publication Date
15 December 2022 (15.12.2022)

(51) International Patent Classification:

A61K 31/341 (2006.01) C07D 233/72 (2006.01)
A61K 31/4178 (2006.01) C07D 307/64 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(21) International Application Number:

PCT/US2022/072790

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

07 June 2022 (07.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/208,273 08 June 2021 (08.06.2021) US

(71) Applicant: **FORESEE PHARMACEUTICALS CO., LTD.**; 17f., No. 3, Park St., Nankang District, Taipei City, 115 (TW).

(72) Inventor; and

(71) Applicant: **LI, Yuhua** [US/US]; c/o Foresee Pharmaceuticals USA, Inc., 550 S. College Ave., Suite 107, Newark, DE 19713 (US).

(72) Inventor: **CHIEN, Benjamin**; c/o Foresee Pharmaceuticals USA, Inc., 550 S. College Ave., Suite 107, Newark, DE 19713 (US).

(74) Agent: **HE, Ming** et al.; Ice Miller LLP, 1735 Market Street, Suite 3900, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: SAFE ADMINISTRATION OF MMP-12 INHIBITOR

(57) Abstract: Methods of safely administering a matrix metalloproteinase 12 (MMP-12) inhibitor by oral administration are described. Also described are methods for providing clinically proven safe treatment of asthma, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis, by oral administration of an MMP-12 inhibitor.

WO 2022/261624 A1